Ventrus Biosciences to merge with Assembly Pharmaceuticals
Combined company will focus on developing Assembly’s first-in-class small molecules for hepatitis B treatment
Register for free to listen to this article
Listen with Speechify
0:00
5:00
NEW YORK—Depending on the outcome of the stockholder meeting scheduled for July 10 (as of press time for this issue), Ventrus Biosciences Inc. will merge with Assembly Pharmaceuticals, a privately held biopharmaceutical company, in an all-stock transaction. Upon the completion of the merger, the combined company will be renamed Assembly Biosciences, Inc. and trade on the Nasdaq Capital Market under the ticker ASMB. When contacted by DDNews, a spokesperson said the company would have no further comment until after the stockholders meet.
Once the merger is complete, the company will focus on the development of Assembly’s novel, first-in-class small molecules to treat, and potentially cure, hepatitis B virus (HBV). HBV is an underappreciated global epidemic with more than 350 million people worldwide chronically infected, Ventrus stated in the release announcing the proposed merger. Chronic HBV infection causes cirrhosis and liver failure, and it is a leading cause of liver cancer. More than 600,000 deaths each year are attributable to HBV. Current treatments can suppress the infection but require lifelong therapy, since fewer than 10 percent of infections are cured using existing therapies.
“We believe this merger has tremendous potential. Assembly has amassed an enormous depth of scientific expertise and created a high-quality drug discovery effort aimed at advancing its potentially curative therapies for HBV,” Dr. Russell Ellison, CEO and chairman of Ventrus, said in prepared remarks. “We believe combining the Ventrus and Assembly management teams, resources and programs will create a robust biopharmaceutical company with the capabilities to develop and commercialize this first-in-class curative approach to an underserved disease that afflicts hundreds of millions of people worldwide.”
“This merger is an outstanding opportunity to progress our HBV platform and expeditiously bring a lead candidate into clinical development,” said Derek Small, chairman and CEO of Assembly. “Our board and management team believe that by joining with Ventrus, we can accelerate the creation of shareholder value as well as the timeline for development of our much-needed HBV therapeutics. We enthusiastically embraced this opportunity after carefully assessing multiple other attractive proposals to advance Assembly to the next stage.”
Assembly has discovered a series of HBV core protein allosteric modulators (CpAMs) and has shown preclinical proof of principle with significant reductions in the HBV “S” antigen in in-vitro experiments. HBV is a DNA-virus and Assembly’s CpAMs target the function of intra-nuclear covalently closed circular DNA (a special DNA structure known as cccDNA), which drives establishment and survival of the virus. The merging companies do not believe that any current therapies modulate its activity directly. Molecules that can modulate cccDNA are expected to have “curative potential.”
Assembly’s CpAMs have shown they can selectively and potently reduce viral load and the key viral antigens HBV “S” antigen (HBsAg) and HBV “E” antigen. Reduction of HBsAg in patients is considered to be the best marker of a functional cure and is a key clinical endpoint in development.
The proposed board and management team would consist of the following Ventrus and Assembly directors and officers: CEO and Chairman Russell Ellison; President, Chief Operating Officer and Director Derek Small, a co-founder of Assembly where he serves as chairman and CEO; Chief Financial Officer David Barrett, who currently holds this title at Ventrus; Vice President of Research and Development and Chief Medical Officer Dr. Uri Lopatin, a co-founder of Assembly; and Chief Scientific Officer Dr. Lee D. Arnold.
Pursuant to the merger agreement, Ventrus will issue approximately 23 million shares of common stock to the Assembly stockholders. At the time of issuance, 20,322,760 of the shares will be issued common stock and 2,829,740 shares will be shares underlying stock options of Assembly. Consummation of this merger, which was expected to be completed by July 10, 2014, is subject to the approval by the Ventrus stockholders. This vote is required to meet NASDAQ requirements. The shares will represent approximately 49 percent of Ventrus’ outstanding shares of common stock immediately after the Assembly merger, on a fully diluted basis.
Ventrus BioSciences is a development-stage specialty pharmaceutical company currently focused on the development of gastrointestinal products (GI), including infections of the GI system. Ventrus believes it has completed clinical development of VEN 307 and has scheduled a meeting with the FDA on June 19, 2014 to discuss the filing of an NDA. Ventrus also has an early-stage program in microbiome therapeutics, VEN 310, which it is developing as an oral colonic delivery mechanism for bacteria, complex proteins, viral antigens and small molecules.
Assembly Pharmaceuticals is a virology-focused biopharmaceutical company with a discovery platform and programs based on CpAMs for the treatment of viral infections, starting with HBV.
